RBC Europe’s BioMarin Pharmaceuticals BMRN Stock Holding History

RBC Europe’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$41K	Hold	500	–	–	﹤0.01%	346
2022 Q1	$39K	Hold	500	–	–	﹤0.01%	382
2021 Q4	$44K	Hold	500	–	–	﹤0.01%	374
2021 Q3	$38.6K	Hold	500	–	–	﹤0.01%	626
2021 Q2	$41.7K	Hold	500	–	–	﹤0.01%	634
2021 Q1	$37.8K	Hold	500	–	–	﹤0.01%	616
2020 Q4	$43.8K	Hold	500	–	–	﹤0.01%	552
2020 Q3	$38K	Hold	500	–	–	﹤0.01%	530
2020 Q2	$61.7K	Sell	500 -105	-17%	-$10.4K	﹤0.01%	403
2020 Q1	$51.1K	Sell	605 -100	-14%	-$8.62K	0.01%	383
2019 Q4	$59.6K	Sell	705 -525	-43%	-$39.7K	0.01%	416
2019 Q3	$82.9K	Sell	1,230 -70	-5%	-$5.39K	0.01%	364
2019 Q2	$111K	Hold	1,300	–	–	0.01%	321
2019 Q1	$115K	Hold	1,300	–	–	0.01%	307
2018 Q4	$111K	Hold	1,300	–	–	0.01%	294
2018 Q3	$126K	Hold	1,300	–	–	0.01%	317
2018 Q2	$122K	Buy	1,300 +800	+160%	+$70.1K	0.01%	324
2018 Q1	$40.5K	Hold	500	–	–	0.01%	502
2017 Q4	$44.6K	Hold	500	–	–	0.01%	490
2017 Q3	$46.5K	Buy	+500	New	+$44.2K	0.01%	485

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RBC Europe's BMRN Position: Q2 2022 in Review

RBC Europe held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2022 at 500 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #346.

RBC Europe first reported a position in BMRN in Q3 2017 and has held it in 20 quarters since. The position peaked at $126K in Q3 2018. 543 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

RBC Europe held 500 shares of BioMarin Pharmaceuticals worth $41K as of Q2 2022.
RBC Europe left its BioMarin Pharmaceuticals share count unchanged in Q2 2022.
BioMarin Pharmaceuticals made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #346 holding.
RBC Europe first reported a position in BioMarin Pharmaceuticals in Q3 2017 and has held it in 20 quarters since.
RBC Europe's BioMarin Pharmaceuticals position peaked at $126K in Q3 2018.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.